Skip to content
Biodatica
Start free

Revolution Medicines, Inc.

Duarte, California

OncologyPhase IIListed · RVMD

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

6w agoTrial registeredJun 3, 2026Source filing (opens the source filing in a new tab)

Momentum

87no change

Momentum 87 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Nov 14, 2023

    Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma · RECRUITING · sponsor: Revolution Medicines, Inc. · Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    ClinicalTrials.gov · NCT06128551 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Sep 7, 2023

    Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors · RECRUITING · sponsor: Revolution Medicines, Inc. · Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    ClinicalTrials.gov · NCT06040541 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Sep 19, 2022

    Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: Revolution Medicines, Inc. · Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

    ClinicalTrials.gov · NCT05462717 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Apr 7, 2021

    Solid Tumors · COMPLETED · sponsor: Revolution Medicines, Inc. · Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

    ClinicalTrials.gov · NCT04774952 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources